SCHEMBL16346576

SCHEMBL16346576

CN1CCN(Cc2ccc(C(=O)Nc3nc(-c4cccc(Br)c4)cs3)cc2)CC1

nearest known ligand 0.77

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ALK Q9UM73 20/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16346652 0.89 ALK (0.69) ALK
SCHEMBL16346055 0.89 ALK (0.71) ALK
SCHEMBL12601800 0.88 ALK (0.77) ALK
SCHEMBL16346578 0.87 ALK (1.00) ALK
SCHEMBL16346366 0.86 ALK (0.71) ALK
SCHEMBL16345898 0.86 ALK (0.68) ALK
SCHEMBL16346010 0.86 ALK (0.71) ALK
SCHEMBL16346580 0.86 ALK (1.00) ALK
SCHEMBL19133247 0.85 ALK (0.85) ALK
SCHEMBL16346486 0.85 ALK (1.00) ALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9708279-B2 2-acylaminothiazoles for the treatment of cancer UNIVERSITÁ DEGLI STUDI DI MILANO—BICOCCA (IT) 2017-07-18 US disclosed
US-9708279-B2 2-acylaminothiazoles for the treatment of cancer UNIVERSITÁ DEGLI STUDI DI MILANO—BICOCCA (IT) 2017-07-18 US disclosed
US-9708279-B2 2-acylaminothiazoles for the treatment of cancer UNIVERSITÁ DEGLI STUDI DI MILANO—BICOCCA (IT) 2017-07-18 US disclosed
EP-3016948-B1 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER UNIVERSITÀ DEGLI STUDI DI MILANO - BICOCCA (IT) 2017-05-10 EP disclosed
EP-3016948-B1 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER UNIVERSITÀ DEGLI STUDI DI MILANO - BICOCCA (IT) 2017-05-10 EP disclosed
US-20160257658-A1 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER UNIVERSITE' CLAUDE BERNARD LYON 1 (FR) 2016-09-08 US disclosed
US-20160257658-A1 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER UNIVERSITE' CLAUDE BERNARD LYON 1 (FR) 2016-09-08 US disclosed
US-20160257658-A1 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER UNIVERSITE' CLAUDE BERNARD LYON 1 (FR) 2016-09-08 US disclosed
EP-3016948-A1 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER Università Degli Studi Di Milano - Bicocca (IT) 2016-05-11 EP disclosed
WO-2015001024-A1 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) 2015-01-08 WO disclosed
WO-2015001024-A1 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) 2015-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160257658-A1 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER ALK, ERBB2, ABL1 ALK 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.